Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Clene Inc's Business Segments
Clene Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Royalty Related Party
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Royalty Related Party0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty Related Party | $ 0 | - |
Revenue by Product & Service Category - FY
- Product82.2%
- Royalty17.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 0 | 82.2% |
| Royalty | $ 0 | 17.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Royalty Related Party0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty Related Party | $ 0 | - |
Description of Clene Inc
Clene Inc is a technology company that specializes in developing and commercializing nanotherapeutics for the treatment of neurodegenerative diseases. The company is focused on creating innovative solutions that can target and repair damaged neurons in the central nervous system, offering new hope for those suffering from diseases such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
One of Clene's main products is CNM-Au8, a novel nanocatalytic therapy that utilizes gold nanoparticles to enhance the cellular bioenergetics of neurons. This unique approach has been shown to improve the functional integrity of nerve cells, resulting in enhanced neuronal communication and potential restoration of lost neurological function.
CNM-Au8 has demonstrated promising results in preclinical and early clinical trials. In animal studies, it has shown the ability to protect neurons from oxidative stress and promote their survival. It has also been found to enhance axonal transport, a key process in nerve cell function, in a variety of disease models.
Furthermore, Clene is actively developing other nanocatalytic therapies targeting specific neurodegenerative conditions. These therapies are designed to address the underlying molecular and cellular dysfunctions associated with each disease, providing a targeted and personalized approach to treatment.
The company's research and development efforts are supported by a team of highly skilled scientists and engineers, many of whom have extensive experience in nanotechnology and neurobiology. They are continuously exploring new approaches and technologies to further improve the efficacy and safety of their therapies.
In addition to its innovative product pipeline, Clene is also engaged in strategic collaborations with leading academic institutions and industry partners. These collaborations aim to accelerate the development and commercialization of Clene's nanotherapeutics, ensuring that patients can benefit from these advanced treatments as soon as possible.
To ensure the successful delivery and administration of its nanocatalytic therapies, Clene has developed advanced manufacturing techniques and quality control protocols. These processes comply with rigorous regulatory standards and are continuously optimized to meet the growing demand for their products.
Clene envisions a future where its nanotherapeutics revolutionize the treatment of neurodegenerative diseases, offering patients a chance at improved quality of life and potentially even a cure. The company is committed to advancing the field of neurology and pushing the boundaries of what is possible in terms of neuronal repair and regeneration.
Overall, Clene Inc is a pioneering technology company that is at the forefront of developing innovative nanotherapeutics for neurodegenerative diseases. With its cutting-edge research, strong collaborations, and commitment to patient care, Clene is poised to make a significant impact in the field of neurology.
One of Clene's main products is CNM-Au8, a novel nanocatalytic therapy that utilizes gold nanoparticles to enhance the cellular bioenergetics of neurons. This unique approach has been shown to improve the functional integrity of nerve cells, resulting in enhanced neuronal communication and potential restoration of lost neurological function.
CNM-Au8 has demonstrated promising results in preclinical and early clinical trials. In animal studies, it has shown the ability to protect neurons from oxidative stress and promote their survival. It has also been found to enhance axonal transport, a key process in nerve cell function, in a variety of disease models.
Furthermore, Clene is actively developing other nanocatalytic therapies targeting specific neurodegenerative conditions. These therapies are designed to address the underlying molecular and cellular dysfunctions associated with each disease, providing a targeted and personalized approach to treatment.
The company's research and development efforts are supported by a team of highly skilled scientists and engineers, many of whom have extensive experience in nanotechnology and neurobiology. They are continuously exploring new approaches and technologies to further improve the efficacy and safety of their therapies.
In addition to its innovative product pipeline, Clene is also engaged in strategic collaborations with leading academic institutions and industry partners. These collaborations aim to accelerate the development and commercialization of Clene's nanotherapeutics, ensuring that patients can benefit from these advanced treatments as soon as possible.
To ensure the successful delivery and administration of its nanocatalytic therapies, Clene has developed advanced manufacturing techniques and quality control protocols. These processes comply with rigorous regulatory standards and are continuously optimized to meet the growing demand for their products.
Clene envisions a future where its nanotherapeutics revolutionize the treatment of neurodegenerative diseases, offering patients a chance at improved quality of life and potentially even a cure. The company is committed to advancing the field of neurology and pushing the boundaries of what is possible in terms of neuronal repair and regeneration.
Overall, Clene Inc is a pioneering technology company that is at the forefront of developing innovative nanotherapeutics for neurodegenerative diseases. With its cutting-edge research, strong collaborations, and commitment to patient care, Clene is poised to make a significant impact in the field of neurology.
Clene Inc. is a biopharmaceutical company focused on developing innovative therapies, particularly in the field of neurodegenerative diseases and disorders. The companys approach is rooted in harnessing and advancing nanotechnology to produce therapeutic solutions designed to target cellular and molecular mechanisms of disease.
Segments
1. Therapeutic Development: Clenes core segment revolves around the research and development of its therapeutic candidates aimed at treating conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative diseases. This segment includes preclinical and clinical development phases, focusing on translating scientific discoveries into viable treatments.
2. Nanotechnology: Clene integrates nanotechnology into its drug formulation strategies. This segment emphasizes the creation of nano-suspensions that enhance drug delivery and efficacy by improving the solubility and bioavailability of therapeutic compounds.
3. Regulatory Affairs: In this segment, the company navigates the complex landscape of drug regulation, engaging with entities such as the FDA to gain approvals for clinical trials, new drug applications, and other regulatory milestones critical to bringing therapies to market.
4. Commercialization and Market Access: Clene’s efforts in this segment include the strategic planning necessary to successfully bring products to market once they receive regulatory approval. This includes establishing partnerships with distributers, health care providers, and payers to ensure that their therapies can effectively reach patients.
Products
1. CNM-Au8: Clene’s lead product candidate, CNM-Au8, is a gold nanocrystal suspension developed to target neurodegeneration. It aims to enhance mitochondrial function, combat oxidative stress, and promote cellular health. Its currently undergoing clinical trials for various neurodegenerative conditions, notably ALS and MS.
2. CNM-ZnO: Another promising product, CNM-ZnO, consists of zinc oxide nanoparticles. This formulation is designed to potentially provide therapeutic benefits in neurological recovery processes. It is being investigated for its role in modulating cellular inflammation and promoting neuroprotection.
3. Pipeline Candidates: Clene has a portfolio of preclinical candidates aimed at addressing various neurological conditions. These exploratory products are in various stages of research and may include other formulations of nanotechnology-based medications aimed at different pathways involved in neurodegeneration.
Services
1. Research and Development Services: Clene engages in extensive R&D activities not only for its own product pipeline but also offers collaborative opportunities with other pharmaceutical firms and academic institutions. This includes shared research agreements, co-development initiatives, and consultancy on drug formulation with a focus on nanotechnology applications.
2. Clinical Trial Management: Clene oversees the management and execution of clinical trials for their therapeutic products. This includes design, implementation, regulatory compliance, and monitoring to ensure that studies meet the necessary ethical and scientific standards.
3. Regulatory Consulting: Clene provides expertise in navigating the regulatory landscape, advising partners on strategies for compliance, submission preparation, and maximizing the probability of approval for new therapeutics.
4. Market Research and Access Strategy: Once products are nearing commercialization, Clene conducts extensive market analysis to identify and understand target demographics, competitive landscapes, and pricing strategies that facilitate market entry and access.
Conclusion
Clene Inc. is positioned at the intersection of innovative drug development and advanced nanotechnology, focusing on addressing significant unmet medical needs in neurodegenerative diseases. Through a multifaceted approach encompassing R&D, regulatory affairs, and strategic market access planning, Clene is committed to advancing its therapeutic candidates for the benefit of patients suffering from debilitating neurological conditions.
Segments
1. Therapeutic Development: Clenes core segment revolves around the research and development of its therapeutic candidates aimed at treating conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative diseases. This segment includes preclinical and clinical development phases, focusing on translating scientific discoveries into viable treatments.
2. Nanotechnology: Clene integrates nanotechnology into its drug formulation strategies. This segment emphasizes the creation of nano-suspensions that enhance drug delivery and efficacy by improving the solubility and bioavailability of therapeutic compounds.
3. Regulatory Affairs: In this segment, the company navigates the complex landscape of drug regulation, engaging with entities such as the FDA to gain approvals for clinical trials, new drug applications, and other regulatory milestones critical to bringing therapies to market.
4. Commercialization and Market Access: Clene’s efforts in this segment include the strategic planning necessary to successfully bring products to market once they receive regulatory approval. This includes establishing partnerships with distributers, health care providers, and payers to ensure that their therapies can effectively reach patients.
Products
1. CNM-Au8: Clene’s lead product candidate, CNM-Au8, is a gold nanocrystal suspension developed to target neurodegeneration. It aims to enhance mitochondrial function, combat oxidative stress, and promote cellular health. Its currently undergoing clinical trials for various neurodegenerative conditions, notably ALS and MS.
2. CNM-ZnO: Another promising product, CNM-ZnO, consists of zinc oxide nanoparticles. This formulation is designed to potentially provide therapeutic benefits in neurological recovery processes. It is being investigated for its role in modulating cellular inflammation and promoting neuroprotection.
3. Pipeline Candidates: Clene has a portfolio of preclinical candidates aimed at addressing various neurological conditions. These exploratory products are in various stages of research and may include other formulations of nanotechnology-based medications aimed at different pathways involved in neurodegeneration.
Services
1. Research and Development Services: Clene engages in extensive R&D activities not only for its own product pipeline but also offers collaborative opportunities with other pharmaceutical firms and academic institutions. This includes shared research agreements, co-development initiatives, and consultancy on drug formulation with a focus on nanotechnology applications.
2. Clinical Trial Management: Clene oversees the management and execution of clinical trials for their therapeutic products. This includes design, implementation, regulatory compliance, and monitoring to ensure that studies meet the necessary ethical and scientific standards.
3. Regulatory Consulting: Clene provides expertise in navigating the regulatory landscape, advising partners on strategies for compliance, submission preparation, and maximizing the probability of approval for new therapeutics.
4. Market Research and Access Strategy: Once products are nearing commercialization, Clene conducts extensive market analysis to identify and understand target demographics, competitive landscapes, and pricing strategies that facilitate market entry and access.
Conclusion
Clene Inc. is positioned at the intersection of innovative drug development and advanced nanotechnology, focusing on addressing significant unmet medical needs in neurodegenerative diseases. Through a multifaceted approach encompassing R&D, regulatory affairs, and strategic market access planning, Clene is committed to advancing its therapeutic candidates for the benefit of patients suffering from debilitating neurological conditions.